Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis

Huaming TanGlobal Medicines Development, Global Innovative Pharma, Pfizer Inc, Groton, CT, USA; Correspondence[email protected]

Hernan ValdezGlobal Medical Affairs, Global Innovative Pharma, Pfizer Inc., New York, NY, USA;

Chris E.M. GriffithsThe Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK;

Ulrich MrowietzPsoriasis-Center at the Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Germany;

Anna TallmanGlobal Medical Affairs, Global Innovative Pharma, Pfizer Inc., New York, NY, USA;

Robert WolkGlobal Medicines Development, Global Innovative Pharma, Pfizer Inc, Groton, CT, USA;

Kenneth GordonDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

show all

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Steven R. Feldman, Joseph F. Merola, David M. Pariser, Jingchuan Zhang, Yang Zhao, Alan M. Mendelsohn & Alice B. Gottlieb. (2022) Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis. Journal of Dermatological Treatment 33:3, pages 1670-1675.
Read now

Luisa Costa, Antonio Del Puente, Rosario Peluso, Marco Tasso, Paolo Caso, Maria Sole Chimenti, Vincenzo Sabbatino, Nicolò Girolimetto, Carolina Benigno, Nicoletta Bertolini, Aurora Del Puente, Roberto Perricone, Raffaele Scarpa & Francesco Caso. (2017) Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opinion on Pharmacotherapy 18:15, pages 1557-1567.
Read now

Articles from other publishers (4)

Deepak R. Jadon, Carmel Stober, Stephen R. Pennington & Oliver FitzGerald. (2020) Applying precision medicine to unmet clinical needs in psoriatic disease. Nature Reviews Rheumatology 16:11, pages 609-627.
Crossref

Lijuan Zhou, Xianqi Zhang, Ralf Paus & Zhongfa Lu. (2018) The renaissance of human skin organ culture: A critical reappraisal. Differentiation 104, pages 22-35.
Crossref

Christopher Banfield, Matthew Scaramozza, Weidong Zhang, Elizabeth Kieras, Karen M. Page, Andrew Fensome, Michael Vincent, Martin E. Dowty, Kosalaram Goteti, Peter J. Winkle & Elena Peeva. (2017) The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis. The Journal of Clinical Pharmacology 58:4, pages 434-447.
Crossref

Alexandra Azevedo & Tiago Torres. (2017) Tofacitinib: A New Oral Therapy for Psoriasis. Clinical Drug Investigation 38:2, pages 101-112.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis

Articles from other publishers (4)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis

Citations (6)

Read on this site (2)

Articles from other publishers (4)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date